nodes	percent_of_prediction	percent_of_DWPC	metapath
Glycopyrrolate—CHRM3—ureter—urinary bladder cancer	0.0955	0.379	CbGeAlD
Glycopyrrolate—CHRM3—muscle of abdomen—urinary bladder cancer	0.0688	0.273	CbGeAlD
Glycopyrrolate—CHRM5—epithelium—urinary bladder cancer	0.0146	0.0581	CbGeAlD
Glycopyrrolate—CHRM2—prostate gland—urinary bladder cancer	0.0137	0.0543	CbGeAlD
Glycopyrrolate—CHRM1—prostate gland—urinary bladder cancer	0.0125	0.0494	CbGeAlD
Glycopyrrolate—CHRM3—prostate gland—urinary bladder cancer	0.0111	0.0442	CbGeAlD
Glycopyrrolate—CHRM3—smooth muscle tissue—urinary bladder cancer	0.00789	0.0313	CbGeAlD
Glycopyrrolate—CHRM3—renal system—urinary bladder cancer	0.0076	0.0301	CbGeAlD
Glycopyrrolate—CHRM3—urethra—urinary bladder cancer	0.00746	0.0296	CbGeAlD
Glycopyrrolate—CHRM1—female reproductive system—urinary bladder cancer	0.0068	0.027	CbGeAlD
Glycopyrrolate—CHRM3—female reproductive system—urinary bladder cancer	0.00608	0.0241	CbGeAlD
Glycopyrrolate—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.00116	0.00155	CcSEcCtD
Glycopyrrolate—Fatigue—Gemcitabine—urinary bladder cancer	0.00116	0.00155	CcSEcCtD
Glycopyrrolate—Confusional state—Etoposide—urinary bladder cancer	0.00116	0.00155	CcSEcCtD
Glycopyrrolate—Cardiac arrest—Doxorubicin—urinary bladder cancer	0.00115	0.00154	CcSEcCtD
Glycopyrrolate—Pain—Gemcitabine—urinary bladder cancer	0.00115	0.00154	CcSEcCtD
Glycopyrrolate—Constipation—Gemcitabine—urinary bladder cancer	0.00115	0.00154	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00115	0.00153	CcSEcCtD
Glycopyrrolate—Mood swings—Doxorubicin—urinary bladder cancer	0.00115	0.00153	CcSEcCtD
Glycopyrrolate—Asthenia—Thiotepa—urinary bladder cancer	0.00115	0.00153	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00114	0.00153	CcSEcCtD
Glycopyrrolate—Infection—Etoposide—urinary bladder cancer	0.00114	0.00152	CcSEcCtD
Glycopyrrolate—Abdominal distension—Epirubicin—urinary bladder cancer	0.00114	0.00152	CcSEcCtD
Glycopyrrolate—Dysuria—Methotrexate—urinary bladder cancer	0.00113	0.00151	CcSEcCtD
Glycopyrrolate—Pruritus—Thiotepa—urinary bladder cancer	0.00113	0.00151	CcSEcCtD
Glycopyrrolate—Pain—Fluorouracil—urinary bladder cancer	0.00113	0.00151	CcSEcCtD
Glycopyrrolate—Dehydration—Doxorubicin—urinary bladder cancer	0.00113	0.00151	CcSEcCtD
Glycopyrrolate—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.00112	0.0015	CcSEcCtD
Glycopyrrolate—Tachycardia—Etoposide—urinary bladder cancer	0.00112	0.0015	CcSEcCtD
Glycopyrrolate—Skin disorder—Etoposide—urinary bladder cancer	0.00112	0.00149	CcSEcCtD
Glycopyrrolate—Erectile dysfunction—Methotrexate—urinary bladder cancer	0.00111	0.00149	CcSEcCtD
Glycopyrrolate—Dry skin—Doxorubicin—urinary bladder cancer	0.00111	0.00148	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Etoposide—urinary bladder cancer	0.00111	0.00148	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.00111	0.00148	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.00109	0.00146	CcSEcCtD
Glycopyrrolate—Pneumonia—Methotrexate—urinary bladder cancer	0.00108	0.00145	CcSEcCtD
Glycopyrrolate—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.00108	0.00145	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.00108	0.00145	CcSEcCtD
Glycopyrrolate—Infestation—Methotrexate—urinary bladder cancer	0.00108	0.00144	CcSEcCtD
Glycopyrrolate—Infestation NOS—Methotrexate—urinary bladder cancer	0.00108	0.00144	CcSEcCtD
Glycopyrrolate—Drowsiness—Methotrexate—urinary bladder cancer	0.00108	0.00144	CcSEcCtD
Glycopyrrolate—Hypotension—Etoposide—urinary bladder cancer	0.00107	0.00143	CcSEcCtD
Glycopyrrolate—Pain—Cisplatin—urinary bladder cancer	0.00107	0.00143	CcSEcCtD
Glycopyrrolate—Body temperature increased—Gemcitabine—urinary bladder cancer	0.00106	0.00142	CcSEcCtD
Glycopyrrolate—Dysuria—Epirubicin—urinary bladder cancer	0.00106	0.00141	CcSEcCtD
Glycopyrrolate—Dizziness—Thiotepa—urinary bladder cancer	0.00106	0.00141	CcSEcCtD
Glycopyrrolate—Abdominal distension—Doxorubicin—urinary bladder cancer	0.00105	0.00141	CcSEcCtD
Glycopyrrolate—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.00105	0.00141	CcSEcCtD
Glycopyrrolate—Urticaria—Fluorouracil—urinary bladder cancer	0.00105	0.0014	CcSEcCtD
Glycopyrrolate—Body temperature increased—Fluorouracil—urinary bladder cancer	0.00104	0.0014	CcSEcCtD
Glycopyrrolate—Sweating—Methotrexate—urinary bladder cancer	0.00103	0.00138	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Cisplatin—urinary bladder cancer	0.00103	0.00138	CcSEcCtD
Glycopyrrolate—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.00102	0.00136	CcSEcCtD
Glycopyrrolate—Somnolence—Etoposide—urinary bladder cancer	0.00102	0.00136	CcSEcCtD
Glycopyrrolate—Epistaxis—Methotrexate—urinary bladder cancer	0.00102	0.00136	CcSEcCtD
Glycopyrrolate—Vomiting—Thiotepa—urinary bladder cancer	0.00102	0.00136	CcSEcCtD
Glycopyrrolate—Pneumonia—Epirubicin—urinary bladder cancer	0.00101	0.00136	CcSEcCtD
Glycopyrrolate—Infestation NOS—Epirubicin—urinary bladder cancer	0.00101	0.00135	CcSEcCtD
Glycopyrrolate—Infestation—Epirubicin—urinary bladder cancer	0.00101	0.00135	CcSEcCtD
Glycopyrrolate—Drowsiness—Epirubicin—urinary bladder cancer	0.00101	0.00135	CcSEcCtD
Glycopyrrolate—Rash—Thiotepa—urinary bladder cancer	0.00101	0.00135	CcSEcCtD
Glycopyrrolate—Dermatitis—Thiotepa—urinary bladder cancer	0.00101	0.00135	CcSEcCtD
Glycopyrrolate—Headache—Thiotepa—urinary bladder cancer	0.001	0.00134	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000991	0.00133	CcSEcCtD
Glycopyrrolate—Body temperature increased—Cisplatin—urinary bladder cancer	0.000991	0.00132	CcSEcCtD
Glycopyrrolate—Fatigue—Etoposide—urinary bladder cancer	0.00099	0.00132	CcSEcCtD
Glycopyrrolate—Constipation—Etoposide—urinary bladder cancer	0.000982	0.00131	CcSEcCtD
Glycopyrrolate—Pain—Etoposide—urinary bladder cancer	0.000982	0.00131	CcSEcCtD
Glycopyrrolate—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000981	0.00131	CcSEcCtD
Glycopyrrolate—Dysuria—Doxorubicin—urinary bladder cancer	0.000979	0.00131	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000974	0.0013	CcSEcCtD
Glycopyrrolate—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000973	0.0013	CcSEcCtD
Glycopyrrolate—Sweating—Epirubicin—urinary bladder cancer	0.000967	0.00129	CcSEcCtD
Glycopyrrolate—Asthenia—Gemcitabine—urinary bladder cancer	0.000965	0.00129	CcSEcCtD
Glycopyrrolate—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000956	0.00128	CcSEcCtD
Glycopyrrolate—Epistaxis—Epirubicin—urinary bladder cancer	0.000952	0.00127	CcSEcCtD
Glycopyrrolate—Pruritus—Gemcitabine—urinary bladder cancer	0.000951	0.00127	CcSEcCtD
Glycopyrrolate—Nausea—Thiotepa—urinary bladder cancer	0.000949	0.00127	CcSEcCtD
Glycopyrrolate—Urethral disorder—Methotrexate—urinary bladder cancer	0.000949	0.00127	CcSEcCtD
Glycopyrrolate—Sinusitis—Epirubicin—urinary bladder cancer	0.000947	0.00127	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Etoposide—urinary bladder cancer	0.000946	0.00126	CcSEcCtD
Glycopyrrolate—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000944	0.00126	CcSEcCtD
Glycopyrrolate—Pneumonia—Doxorubicin—urinary bladder cancer	0.000939	0.00126	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000939	0.00126	CcSEcCtD
Glycopyrrolate—Pruritus—Fluorouracil—urinary bladder cancer	0.000935	0.00125	CcSEcCtD
Glycopyrrolate—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000934	0.00125	CcSEcCtD
Glycopyrrolate—Drowsiness—Doxorubicin—urinary bladder cancer	0.000934	0.00125	CcSEcCtD
Glycopyrrolate—Infestation—Doxorubicin—urinary bladder cancer	0.000934	0.00125	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000923	0.00123	CcSEcCtD
Glycopyrrolate—Urticaria—Etoposide—urinary bladder cancer	0.000912	0.00122	CcSEcCtD
Glycopyrrolate—Rhinitis—Epirubicin—urinary bladder cancer	0.000908	0.00121	CcSEcCtD
Glycopyrrolate—Abdominal pain—Etoposide—urinary bladder cancer	0.000907	0.00121	CcSEcCtD
Glycopyrrolate—Body temperature increased—Etoposide—urinary bladder cancer	0.000907	0.00121	CcSEcCtD
Glycopyrrolate—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000907	0.00121	CcSEcCtD
Glycopyrrolate—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000901	0.0012	CcSEcCtD
Glycopyrrolate—Asthenia—Cisplatin—urinary bladder cancer	0.000899	0.0012	CcSEcCtD
Glycopyrrolate—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000898	0.0012	CcSEcCtD
Glycopyrrolate—Sweating—Doxorubicin—urinary bladder cancer	0.000895	0.0012	CcSEcCtD
Glycopyrrolate—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000894	0.0012	CcSEcCtD
Glycopyrrolate—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.00089	0.00119	CcSEcCtD
Glycopyrrolate—Urethral disorder—Epirubicin—urinary bladder cancer	0.000888	0.00119	CcSEcCtD
Glycopyrrolate—Epistaxis—Doxorubicin—urinary bladder cancer	0.000881	0.00118	CcSEcCtD
Glycopyrrolate—Sinusitis—Doxorubicin—urinary bladder cancer	0.000876	0.00117	CcSEcCtD
Glycopyrrolate—Dizziness—Fluorouracil—urinary bladder cancer	0.000874	0.00117	CcSEcCtD
Glycopyrrolate—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000872	0.00117	CcSEcCtD
Glycopyrrolate—Vomiting—Gemcitabine—urinary bladder cancer	0.000855	0.00114	CcSEcCtD
Glycopyrrolate—Mental disorder—Methotrexate—urinary bladder cancer	0.000848	0.00113	CcSEcCtD
Glycopyrrolate—Rash—Gemcitabine—urinary bladder cancer	0.000848	0.00113	CcSEcCtD
Glycopyrrolate—Dermatitis—Gemcitabine—urinary bladder cancer	0.000847	0.00113	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Etoposide—urinary bladder cancer	0.000846	0.00113	CcSEcCtD
Glycopyrrolate—Erythema—Methotrexate—urinary bladder cancer	0.000843	0.00113	CcSEcCtD
Glycopyrrolate—Malnutrition—Methotrexate—urinary bladder cancer	0.000843	0.00113	CcSEcCtD
Glycopyrrolate—Headache—Gemcitabine—urinary bladder cancer	0.000842	0.00113	CcSEcCtD
Glycopyrrolate—Flushing—Epirubicin—urinary bladder cancer	0.000841	0.00112	CcSEcCtD
Glycopyrrolate—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000841	0.00112	CcSEcCtD
Glycopyrrolate—Vomiting—Fluorouracil—urinary bladder cancer	0.00084	0.00112	CcSEcCtD
Glycopyrrolate—Rhinitis—Doxorubicin—urinary bladder cancer	0.00084	0.00112	CcSEcCtD
Glycopyrrolate—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000834	0.00111	CcSEcCtD
Glycopyrrolate—Rash—Fluorouracil—urinary bladder cancer	0.000833	0.00111	CcSEcCtD
Glycopyrrolate—Dermatitis—Fluorouracil—urinary bladder cancer	0.000833	0.00111	CcSEcCtD
Glycopyrrolate—Headache—Fluorouracil—urinary bladder cancer	0.000828	0.00111	CcSEcCtD
Glycopyrrolate—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000828	0.00111	CcSEcCtD
Glycopyrrolate—Dysgeusia—Methotrexate—urinary bladder cancer	0.000825	0.0011	CcSEcCtD
Glycopyrrolate—Asthenia—Etoposide—urinary bladder cancer	0.000824	0.0011	CcSEcCtD
Glycopyrrolate—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000824	0.0011	CcSEcCtD
Glycopyrrolate—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000822	0.0011	CcSEcCtD
Glycopyrrolate—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000816	0.00109	CcSEcCtD
Glycopyrrolate—Pruritus—Etoposide—urinary bladder cancer	0.000812	0.00109	CcSEcCtD
Glycopyrrolate—Nausea—Gemcitabine—urinary bladder cancer	0.000799	0.00107	CcSEcCtD
Glycopyrrolate—Vomiting—Cisplatin—urinary bladder cancer	0.000797	0.00107	CcSEcCtD
Glycopyrrolate—Vision blurred—Methotrexate—urinary bladder cancer	0.000794	0.00106	CcSEcCtD
Glycopyrrolate—Mental disorder—Epirubicin—urinary bladder cancer	0.000794	0.00106	CcSEcCtD
Glycopyrrolate—Rash—Cisplatin—urinary bladder cancer	0.00079	0.00106	CcSEcCtD
Glycopyrrolate—Dermatitis—Cisplatin—urinary bladder cancer	0.000789	0.00106	CcSEcCtD
Glycopyrrolate—Erythema—Epirubicin—urinary bladder cancer	0.000788	0.00105	CcSEcCtD
Glycopyrrolate—Malnutrition—Epirubicin—urinary bladder cancer	0.000788	0.00105	CcSEcCtD
Glycopyrrolate—Nausea—Fluorouracil—urinary bladder cancer	0.000785	0.00105	CcSEcCtD
Glycopyrrolate—Flushing—Doxorubicin—urinary bladder cancer	0.000778	0.00104	CcSEcCtD
Glycopyrrolate—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000778	0.00104	CcSEcCtD
Glycopyrrolate—Flatulence—Epirubicin—urinary bladder cancer	0.000777	0.00104	CcSEcCtD
Glycopyrrolate—Tension—Epirubicin—urinary bladder cancer	0.000774	0.00103	CcSEcCtD
Glycopyrrolate—Dysgeusia—Epirubicin—urinary bladder cancer	0.000772	0.00103	CcSEcCtD
Glycopyrrolate—Nervousness—Epirubicin—urinary bladder cancer	0.000766	0.00102	CcSEcCtD
Glycopyrrolate—Dizziness—Etoposide—urinary bladder cancer	0.000759	0.00101	CcSEcCtD
Glycopyrrolate—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000755	0.00101	CcSEcCtD
Glycopyrrolate—Nausea—Cisplatin—urinary bladder cancer	0.000744	0.000995	CcSEcCtD
Glycopyrrolate—Vision blurred—Epirubicin—urinary bladder cancer	0.000743	0.000994	CcSEcCtD
Glycopyrrolate—Mental disorder—Doxorubicin—urinary bladder cancer	0.000734	0.000982	CcSEcCtD
Glycopyrrolate—Convulsion—Methotrexate—urinary bladder cancer	0.00073	0.000976	CcSEcCtD
Glycopyrrolate—Vomiting—Etoposide—urinary bladder cancer	0.00073	0.000976	CcSEcCtD
Glycopyrrolate—Malnutrition—Doxorubicin—urinary bladder cancer	0.00073	0.000975	CcSEcCtD
Glycopyrrolate—Erythema—Doxorubicin—urinary bladder cancer	0.00073	0.000975	CcSEcCtD
Glycopyrrolate—Agitation—Epirubicin—urinary bladder cancer	0.000725	0.000969	CcSEcCtD
Glycopyrrolate—Rash—Etoposide—urinary bladder cancer	0.000724	0.000968	CcSEcCtD
Glycopyrrolate—Dermatitis—Etoposide—urinary bladder cancer	0.000723	0.000967	CcSEcCtD
Glycopyrrolate—Headache—Etoposide—urinary bladder cancer	0.000719	0.000962	CcSEcCtD
Glycopyrrolate—Flatulence—Doxorubicin—urinary bladder cancer	0.000719	0.000961	CcSEcCtD
Glycopyrrolate—Tension—Doxorubicin—urinary bladder cancer	0.000716	0.000957	CcSEcCtD
Glycopyrrolate—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000714	0.000955	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000712	0.000952	CcSEcCtD
Glycopyrrolate—Nervousness—Doxorubicin—urinary bladder cancer	0.000709	0.000947	CcSEcCtD
Glycopyrrolate—Palpitations—Epirubicin—urinary bladder cancer	0.000697	0.000932	CcSEcCtD
Glycopyrrolate—Confusional state—Methotrexate—urinary bladder cancer	0.000693	0.000927	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000688	0.000919	CcSEcCtD
Glycopyrrolate—Vision blurred—Doxorubicin—urinary bladder cancer	0.000688	0.000919	CcSEcCtD
Glycopyrrolate—Convulsion—Epirubicin—urinary bladder cancer	0.000683	0.000913	CcSEcCtD
Glycopyrrolate—Infection—Methotrexate—urinary bladder cancer	0.000683	0.000913	CcSEcCtD
Glycopyrrolate—Nausea—Etoposide—urinary bladder cancer	0.000682	0.000912	CcSEcCtD
Glycopyrrolate—Hypertension—Epirubicin—urinary bladder cancer	0.000681	0.00091	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000674	0.000902	CcSEcCtD
Glycopyrrolate—Agitation—Doxorubicin—urinary bladder cancer	0.00067	0.000896	CcSEcCtD
Glycopyrrolate—Skin disorder—Methotrexate—urinary bladder cancer	0.000668	0.000893	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000667	0.000891	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000665	0.000889	CcSEcCtD
Glycopyrrolate—Dry mouth—Epirubicin—urinary bladder cancer	0.000656	0.000878	CcSEcCtD
Glycopyrrolate—Confusional state—Epirubicin—urinary bladder cancer	0.000649	0.000868	CcSEcCtD
Glycopyrrolate—Palpitations—Doxorubicin—urinary bladder cancer	0.000645	0.000862	CcSEcCtD
Glycopyrrolate—Oedema—Epirubicin—urinary bladder cancer	0.000643	0.00086	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000643	0.00086	CcSEcCtD
Glycopyrrolate—Hypotension—Methotrexate—urinary bladder cancer	0.000643	0.000859	CcSEcCtD
Glycopyrrolate—Infection—Epirubicin—urinary bladder cancer	0.000639	0.000855	CcSEcCtD
Glycopyrrolate—Convulsion—Doxorubicin—urinary bladder cancer	0.000632	0.000845	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000631	0.000844	CcSEcCtD
Glycopyrrolate—Hypertension—Doxorubicin—urinary bladder cancer	0.00063	0.000842	CcSEcCtD
Glycopyrrolate—Tachycardia—Epirubicin—urinary bladder cancer	0.000628	0.00084	CcSEcCtD
Glycopyrrolate—Skin disorder—Epirubicin—urinary bladder cancer	0.000625	0.000836	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000622	0.000832	CcSEcCtD
Glycopyrrolate—Insomnia—Methotrexate—urinary bladder cancer	0.000622	0.000832	CcSEcCtD
Glycopyrrolate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000617	0.000825	CcSEcCtD
Glycopyrrolate—Somnolence—Methotrexate—urinary bladder cancer	0.000611	0.000817	CcSEcCtD
Glycopyrrolate—Dry mouth—Doxorubicin—urinary bladder cancer	0.000607	0.000812	CcSEcCtD
Glycopyrrolate—Dyspepsia—Methotrexate—urinary bladder cancer	0.000605	0.000809	CcSEcCtD
Glycopyrrolate—Hypotension—Epirubicin—urinary bladder cancer	0.000601	0.000804	CcSEcCtD
Glycopyrrolate—Confusional state—Doxorubicin—urinary bladder cancer	0.0006	0.000803	CcSEcCtD
Glycopyrrolate—Oedema—Doxorubicin—urinary bladder cancer	0.000595	0.000796	CcSEcCtD
Glycopyrrolate—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000595	0.000796	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000594	0.000794	CcSEcCtD
Glycopyrrolate—Fatigue—Methotrexate—urinary bladder cancer	0.000593	0.000793	CcSEcCtD
Glycopyrrolate—Infection—Doxorubicin—urinary bladder cancer	0.000592	0.000791	CcSEcCtD
Glycopyrrolate—Pain—Methotrexate—urinary bladder cancer	0.000588	0.000786	CcSEcCtD
Glycopyrrolate—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000584	0.000781	CcSEcCtD
Glycopyrrolate—Insomnia—Epirubicin—urinary bladder cancer	0.000582	0.000778	CcSEcCtD
Glycopyrrolate—Tachycardia—Doxorubicin—urinary bladder cancer	0.000581	0.000777	CcSEcCtD
Glycopyrrolate—Skin disorder—Doxorubicin—urinary bladder cancer	0.000578	0.000773	CcSEcCtD
Glycopyrrolate—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000576	0.00077	CcSEcCtD
Glycopyrrolate—Somnolence—Epirubicin—urinary bladder cancer	0.000572	0.000765	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000567	0.000758	CcSEcCtD
Glycopyrrolate—Dyspepsia—Epirubicin—urinary bladder cancer	0.000566	0.000757	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000562	0.000752	CcSEcCtD
Glycopyrrolate—Hypotension—Doxorubicin—urinary bladder cancer	0.000556	0.000744	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000556	0.000743	CcSEcCtD
Glycopyrrolate—Fatigue—Epirubicin—urinary bladder cancer	0.000555	0.000742	CcSEcCtD
Glycopyrrolate—Constipation—Epirubicin—urinary bladder cancer	0.00055	0.000736	CcSEcCtD
Glycopyrrolate—Pain—Epirubicin—urinary bladder cancer	0.00055	0.000736	CcSEcCtD
Glycopyrrolate—Urticaria—Methotrexate—urinary bladder cancer	0.000546	0.00073	CcSEcCtD
Glycopyrrolate—Abdominal pain—Methotrexate—urinary bladder cancer	0.000544	0.000727	CcSEcCtD
Glycopyrrolate—Body temperature increased—Methotrexate—urinary bladder cancer	0.000544	0.000727	CcSEcCtD
Glycopyrrolate—Insomnia—Doxorubicin—urinary bladder cancer	0.000539	0.00072	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Epirubicin—urinary bladder cancer	0.00053	0.000709	CcSEcCtD
Glycopyrrolate—Somnolence—Doxorubicin—urinary bladder cancer	0.000529	0.000708	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000526	0.000704	CcSEcCtD
Glycopyrrolate—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000524	0.000701	CcSEcCtD
Glycopyrrolate—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000514	0.000687	CcSEcCtD
Glycopyrrolate—Fatigue—Doxorubicin—urinary bladder cancer	0.000513	0.000686	CcSEcCtD
Glycopyrrolate—Urticaria—Epirubicin—urinary bladder cancer	0.000511	0.000684	CcSEcCtD
Glycopyrrolate—Pain—Doxorubicin—urinary bladder cancer	0.000509	0.000681	CcSEcCtD
Glycopyrrolate—Constipation—Doxorubicin—urinary bladder cancer	0.000509	0.000681	CcSEcCtD
Glycopyrrolate—Body temperature increased—Epirubicin—urinary bladder cancer	0.000509	0.00068	CcSEcCtD
Glycopyrrolate—Abdominal pain—Epirubicin—urinary bladder cancer	0.000509	0.00068	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000507	0.000677	CcSEcCtD
Glycopyrrolate—Asthenia—Methotrexate—urinary bladder cancer	0.000493	0.00066	CcSEcCtD
Glycopyrrolate—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000491	0.000656	CcSEcCtD
Glycopyrrolate—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000487	0.000651	CcSEcCtD
Glycopyrrolate—Pruritus—Methotrexate—urinary bladder cancer	0.000486	0.00065	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000474	0.000634	CcSEcCtD
Glycopyrrolate—Urticaria—Doxorubicin—urinary bladder cancer	0.000473	0.000632	CcSEcCtD
Glycopyrrolate—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000471	0.000629	CcSEcCtD
Glycopyrrolate—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000471	0.000629	CcSEcCtD
Glycopyrrolate—Asthenia—Epirubicin—urinary bladder cancer	0.000462	0.000617	CcSEcCtD
Glycopyrrolate—Pruritus—Epirubicin—urinary bladder cancer	0.000455	0.000609	CcSEcCtD
Glycopyrrolate—Dizziness—Methotrexate—urinary bladder cancer	0.000455	0.000608	CcSEcCtD
Glycopyrrolate—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000439	0.000587	CcSEcCtD
Glycopyrrolate—Vomiting—Methotrexate—urinary bladder cancer	0.000437	0.000585	CcSEcCtD
Glycopyrrolate—Rash—Methotrexate—urinary bladder cancer	0.000434	0.00058	CcSEcCtD
Glycopyrrolate—Dermatitis—Methotrexate—urinary bladder cancer	0.000433	0.000579	CcSEcCtD
Glycopyrrolate—Headache—Methotrexate—urinary bladder cancer	0.000431	0.000576	CcSEcCtD
Glycopyrrolate—Asthenia—Doxorubicin—urinary bladder cancer	0.000427	0.000571	CcSEcCtD
Glycopyrrolate—Dizziness—Epirubicin—urinary bladder cancer	0.000426	0.000569	CcSEcCtD
Glycopyrrolate—Pruritus—Doxorubicin—urinary bladder cancer	0.000421	0.000563	CcSEcCtD
Glycopyrrolate—Vomiting—Epirubicin—urinary bladder cancer	0.000409	0.000547	CcSEcCtD
Glycopyrrolate—Nausea—Methotrexate—urinary bladder cancer	0.000408	0.000546	CcSEcCtD
Glycopyrrolate—Rash—Epirubicin—urinary bladder cancer	0.000406	0.000542	CcSEcCtD
Glycopyrrolate—Dermatitis—Epirubicin—urinary bladder cancer	0.000405	0.000542	CcSEcCtD
Glycopyrrolate—Headache—Epirubicin—urinary bladder cancer	0.000403	0.000539	CcSEcCtD
Glycopyrrolate—Dizziness—Doxorubicin—urinary bladder cancer	0.000394	0.000526	CcSEcCtD
Glycopyrrolate—Nausea—Epirubicin—urinary bladder cancer	0.000382	0.000511	CcSEcCtD
Glycopyrrolate—Vomiting—Doxorubicin—urinary bladder cancer	0.000379	0.000506	CcSEcCtD
Glycopyrrolate—Rash—Doxorubicin—urinary bladder cancer	0.000375	0.000502	CcSEcCtD
Glycopyrrolate—Dermatitis—Doxorubicin—urinary bladder cancer	0.000375	0.000501	CcSEcCtD
Glycopyrrolate—Headache—Doxorubicin—urinary bladder cancer	0.000373	0.000499	CcSEcCtD
Glycopyrrolate—Nausea—Doxorubicin—urinary bladder cancer	0.000354	0.000473	CcSEcCtD
